Atomo Diagnostics capitalises on Lumos Diagnostics’ FebriDx FDA CLIA waiver with over $2 million in new sales orders and a $3 million capital raise, expanding its global footprint and product pipeline.
- FDA CLIA waiver boosts US Pascal cassette demand
- Over $2 million in sales orders secured in Q3
- $3 million capital raise completed, debt-free balance sheet
- New international customers and expanded product pipeline
- EBITDA trending towards breakeven with strategic investments
FDA CLIA Waiver Unlocks US Market Surge
Atomo Diagnostics (ASX:AT1) has leveraged the recent FDA CLIA waiver approval for Lumos Diagnostics’ FebriDx test to unlock significant growth in the US market for its proprietary Pascal cassettes. This regulatory milestone expands the US addressable market for Pascal-enabled tests by roughly 15 times, with Lumos anticipating up to US$313 million in FebriDx product revenues over the next six years. Each FebriDx test sold translates directly into Pascal cassette orders for Atomo, creating a scalable revenue stream that saw a staggering 1,600% increase in Pascal orders in the first half of FY26 compared to the previous year.
The CLIA waiver not only validates Atomo’s cassette technology but also establishes a predicate pathway for Atomo’s own diagnostic products to enter the lucrative US market. This breakthrough is a pivotal moment for Atomo, confirming the commercial viability of its Pascal platform and catalysing expansion opportunities with new international customers recently secured in the UK and Canada. These developments build on the company’s ongoing efforts to scale production and meet rising demand, positioning Atomo as a critical supplier in the global point-of-care diagnostics landscape. This follows the company's recent Pascal Cassette Powers FebriDx milestone that set the stage for this growth.
Robust Sales and Capital Strengthen Growth Trajectory
During Q3 FY26, Atomo secured sales orders exceeding $2 million, including a $500,000 HIV order for African low- and middle-income countries (LMICs) and a $630,000 order from the National Association of People with HIV Australia (NAPWHA). These orders underscore the company’s expanding footprint in both established and emerging markets, supported by its portfolio of HIV self-tests and Pascal cassette supply agreements. Revenue for the quarter reached $814,000, with year-to-date revenue around $3 million, marking a 4% increase over the comparable period last year.
Atomo’s financial position remains solid with $2.6 million cash on hand and a debt-free balance sheet. The company completed a $3 million capital raise in April to fund ongoing product development, commercialisation efforts, and capacity expansion. Operating expenses for the quarter were managed at $1.8 million, with additional income from government grants and R&D rebates improving the bottom line by approximately 15-20%. This financial discipline supports Atomo’s strategic aim of driving EBITDA towards breakeven as revenue streams mature.
Expanding Product Pipeline and Global Reach
Beyond Pascal, Atomo is advancing its product pipeline with novel tests targeting active syphilis and liver function, both addressing significant unmet clinical needs. The active syphilis test is unique in its ability to distinguish between active and prior treated infections, with clinical trials scheduled to commence in 2026. Atomo plans to leverage its existing HIV commercial infrastructure to accelerate market entry for this test, capitalising on shared distribution channels and procurement bodies.
The company also secured an exclusive global license for a novel liver function test, addressing large markets in drug-induced liver injury monitoring, fatty liver disease screening, hepatitis management, and alcoholic liver disease detection. These indications collectively represent serviceable obtainable markets valued in the hundreds of millions of dollars by 2032, highlighting Atomo’s potential to diversify and scale its diagnostics portfolio.
Operationally, Atomo is scaling its manufacturing and supply capabilities across multiple continents, with facilities and partnerships in Australia, Europe, North America, China, and South Africa. This global infrastructure supports both Atomo’s finished test products and the Pascal cassette supply chain, ensuring responsiveness to growing demand. The company’s extensive intellectual property portfolio, covering seven patent families across more than 30 countries, underpins its competitive advantage and supports its expanding international registrations and market access.
Atomo’s growth momentum is further evidenced by its continued success in the HIV self-test market, particularly in Australia and New Zealand where it holds over 85% market share. The company is executing a clear expansion strategy through pharmacy rollout, channel diversification, and increasing public health procurement, building on established programs and partnerships. This strategy is expected to drive sustained revenue growth and deepen Atomo’s presence in funded and higher-margin markets. Recent sales orders from African countries backed by the Global Fund illustrate this international traction, complementing the company’s domestic market strength and HIV Self-Test Order Backed government program partnerships.
Bottom Line?
Atomo’s FDA CLIA waiver-fuelled US expansion and diversified pipeline position it for scaling revenues, though execution risks remain in commercialising novel diagnostics.
Questions in the middle?
- How quickly can Atomo convert its syphilis and liver test pipelines into commercial revenues?
- Will the US market expansion via FebriDx sustain growth beyond contracted volumes?
- How effectively can Atomo scale manufacturing to meet rising global demand without margin pressure?